{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:18:39Z","timestamp":1791173919349,"version":"4.1.0"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2012,12,31]]},"DOI":"10.18632\/oncotarget.791","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T21:48:09Z","timestamp":1442440089000},"page":"1688-1699","source":"Crossref","is-referenced-by-count":15,"title":["Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway"],"prefix":"10.18632","volume":"3","author":[{"given":"Guillaume","family":"Robert","sequence":"first","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Equipe 2: Morts Cellulaires, Diff\u00e9renciation, inflammation et Cancer"},{"name":"Equipe labellis\u00e9e par la Ligue Nationale Contre le Cancer 2011-2013"},{"name":"Universit\u00e9 de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Jullian","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse; Universit\u00e9 Paul Sabatier; Pharma-Dev UMR 152; Facult\u00e9 de Pharmacie; 35 Chemin des mara\u00eechers, F-31062, Toulouse cedex 9, France"},{"name":"Institut de Recherche pour le D\u00e9veloppement (IRD); Pharma-Dev UMR 152; Facult\u00e9 de Pharmacie, 35 Chemin des mara\u00eechers, F-31062, Toulouse cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jacquel","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Equipe 2: Morts Cellulaires, Diff\u00e9renciation, inflammation et Cancer"},{"name":"Equipe labellis\u00e9e par la Ligue Nationale Contre le Cancer 2011-2013"},{"name":"Universit\u00e9 de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Ginet","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Equipe 2: Morts Cellulaires, Diff\u00e9renciation, inflammation et Cancer"},{"name":"Equipe labellis\u00e9e par la Ligue Nationale Contre le Cancer 2011-2013"},{"name":"Universit\u00e9 de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Dufies","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Equipe 2: Morts Cellulaires, Diff\u00e9renciation, inflammation et Cancer"},{"name":"Equipe labellis\u00e9e par la Ligue Nationale Contre le Cancer 2011-2013"},{"name":"Universit\u00e9 de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Torino","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Universit\u00e9 de Nice, France"},{"name":"Equipe 6: Toxines microbiennes dans la relation h\u00f4te-pathog\u00e8nes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Pottier","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Universit\u00e9 de Nice, France"},{"name":"Equipe 11, Microenvironnement, Signalisation et Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Peyrade","sequence":"additional","affiliation":[{"name":"Centre Antoine Lacassagne, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tartare-Deckert","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Universit\u00e9 de Nice, France"},{"name":"Equipe 11, Microenvironnement, Signalisation et Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Bourdy","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse; Universit\u00e9 Paul Sabatier; Pharma-Dev UMR 152; Facult\u00e9 de Pharmacie; 35 Chemin des mara\u00eechers, F-31062, Toulouse cedex 9, France"},{"name":"Institut de Recherche pour le D\u00e9veloppement (IRD); Pharma-Dev UMR 152; Facult\u00e9 de Pharmacie, 35 Chemin des mara\u00eechers, F-31062, Toulouse cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deharo","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse; Universit\u00e9 Paul Sabatier; Pharma-Dev UMR 152; Facult\u00e9 de Pharmacie; 35 Chemin des mara\u00eechers, F-31062, Toulouse cedex 9, France"},{"name":"Institut de Recherche pour le D\u00e9veloppement (IRD); Pharma-Dev UMR 152; Facult\u00e9 de Pharmacie, 35 Chemin des mara\u00eechers, F-31062, Toulouse cedex 9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Auberger","sequence":"additional","affiliation":[{"name":"INSERM\/U1065, C3M, Nice, France"},{"name":"Equipe 2: Morts Cellulaires, Diff\u00e9renciation, inflammation et Cancer"},{"name":"Equipe labellis\u00e9e par la Ligue Nationale Contre le Cancer 2011-2013"},{"name":"Universit\u00e9 de Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2012,12,30]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1128\/AAC.00951-09","article-title":"Antimalarial activity of simalikalactone E, a new quassinoid from Quassia amara L. (Simaroubaceae)","volume":"53","author":"Jullian","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2011.66","article-title":"Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy","volume":"25","author":"McCubrey","year":"2011","journal-title":"Leukemia"},{"key":"3","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Der","year":"2007","journal-title":"Oncogene"},{"key":"4","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Botti","year":"2012","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/sj.onc.1209379","article-title":"Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma","volume":"25","author":"Anichini","year":"2006","journal-title":"Oncogene"},{"key":"6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bcp.2010.03.019","article-title":"BRAF as therapeutic target in melanoma","volume":"80","author":"Hurlstone","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Rollins","year":"2010","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1210\/jc.2003-031425","article-title":"BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas","volume":"89","author":"Pinchera","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.25555","article-title":"Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation","volume":"128","author":"Desai","year":"2011","journal-title":"Int J Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Ambrosetti","year":"2011","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2011-08-371179","article-title":"Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation","volume":"119","author":"Falini","year":"2012","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1309\/AJCPL0OPXI9LZITV","article-title":"Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay","volume":"138","author":"Patel","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"13","doi-asserted-by":"crossref","first-page":"20411","DOI":"10.1073\/pnas.0905833106","article-title":"MEK1 mutations confer resistance to MEK and B-RAF inhibition","volume":"106","author":"Garraway","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Amaravadi","year":"2012","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/0008-5472.CAN-11-1875","article-title":"Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation","volume":"72","author":"Rosinski","year":"2012","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMc1202124","article-title":"BRAF inhibition in refractory hairy-cell leukemia","volume":"366","author":"Zenz","year":"2012","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Auberger","year":"2003","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1096\/fj.07-101394","article-title":"Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol","volume":"22","author":"Auberger","year":"2008","journal-title":"FASEB J"},{"key":"19","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/cdd.2012.55","article-title":"The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production","volume":"19","author":"Auberger","year":"2012","journal-title":"Cell Death Differ"},{"key":"20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jmcb\/mjs010","article-title":"Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness","volume":"4","author":"Luciano","year":"2012","journal-title":"J Mol Cell Biol"},{"key":"21","doi-asserted-by":"crossref","first-page":"35849","DOI":"10.1074\/jbc.M401580200","article-title":"Activation and proteasomal degradation of rho GTPases by cytotoxic necrotizing factor-1 elicit a controlled inflammatory response","volume":"279","author":"Lemichez","year":"2004","journal-title":"J Biol Chem"},{"key":"22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Brown","year":"2010","journal-title":"Cancer Cell"},{"key":"23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and Deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR Cascades","volume":"3","author":"Milella","year":"2012","journal-title":"Oncotarget"},{"key":"24","first-page":"192","article-title":"Roles of the Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging","volume":"3","author":"Milella","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Mijatovic","year":"2011","journal-title":"Oncotarget"},{"key":"26","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Auberger","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70","author":"Auberger","year":"2010","journal-title":"Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Talpaz","year":"2003","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.4049\/jimmunol.168.10.5303","article-title":"Inhibition of mitogen-activated protein kinase signaling by chloroquine","volume":"168","author":"Levitz","year":"2002","journal-title":"J Immunol"},{"key":"30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrd2272","article-title":"Potential therapeutic applications of autophagy","volume":"6","author":"Klionsky","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"31","doi-asserted-by":"crossref","first-page":"14333","DOI":"10.1073\/pnas.1000248107","article-title":"Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)","volume":"107","author":"Rubin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Vigneri","year":"2009","journal-title":"J Clin Invest"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T11:42:05Z","timestamp":1599565325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,30]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["791","23518796"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.791","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,30]]}}}